Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myelomaAccess, MPE, Myeloma18 April 2024
MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulationAccess, MPE8 April 2024
Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”AL amyloidosis, MPE27 March 2024
Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”MPE, Myeloma25 March 2024
Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”MPE, Myeloma8 March 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, Myeloma22 February 2024
AMEN provides medical information for Arabic speakers in Israel and beyondAccess, MPE13 February 2024
ASH 2023 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, MPE, Myeloma15 December 2023
EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisationAccess, MPE15 December 2023
